Condition
Metastatic Triple Negative Breast Cancers clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Metastatic Triple Negative Breast Cancers clinical trials that are recruiting, at sites in 2 countries (most in United States (1), Singapore (1)). By phase: Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Antibody-drug conjugates for first- and second-line treatment of metastatic HER2‑negative and triple‑negative breast cancer
This prospective registry will collect real-world data to see how FDA-approved antibody-drug conjugates work as first- or second-line treatments for adults with metastatic HER2‑negative or triple-negative breast cancer.
-
Combining Selinexor and Talazoparib for Advanced Triple Negative Breast Cancer
This study is testing a combination of two drugs, Selinexor and Talazoparib, to see if they can help people with advanced triple negative breast cancer.
Related topics
Quick answers
How many Metastatic Triple Negative Breast Cancers clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (1 trial), Singapore (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.